Session Title: Free Paper Session 18: New Drug & Treatment Technology
Session Date/Time: Saturday 09/09/2017 | 14:30-16:00
Paper Time: 15:24
Venue: Room 120
First Author: : C.Kucukerdonmez TURKEY
Co Author(s): : O. Oner T. Ozturk E. Cinar Z. Ayhan H. Oner A. Saatci
To compare the efficacy and safety of half-fluence photodynamic therapy (PDT) and sub-treshold micropulse laser (SML) treatment in patients with chronic central serous retinopathy (CSR).
Retrospective, interventional, comparative study conducted in patients at Izmir Dokuz Eylül University and Izmir Medicalpark Hospital Ophthalmology Clinics.
Forty-seven eyes of 45 patients with CSR diagnosed by clinical examination, florescein angiography and optical coherence tomography were included in this study. All patients had a history of the disease at least 6 months after first diagnosis. Twenty-seven eyes of 26 patients received half-fluence (25mj/cm2) PDT therapy, whereas 20 eyes of 19 patients underwent SML. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at the baseline and after the treatment at first, 6th and 12th months.
The main duration of follow-up after treatment were 16.9±23.9 months (range, 3-120) in the PDT group and 6.6±3.8 months (range, 4-20) in the SML group. The mean BCVA improved from 0.50±0.22 (logMAR) at the baseline to 0.60±0.24 at the end of the follow-up in the PDT group, and from 0.65±0.17 to 0.79±0.20 in the SML group (p=0.051, p=0.058, respectively). The amount of improvement in BCVA between two groups was not significantly different (p=0.437). After treatment, mean CMT decreased from 358.3±142.0 μm at the baseline to 222.3±79.2 μm at the end of the follow-up in the PDT group, and from 355.3±82.0 μm to 198.7±44.7 μm in the SML group (p=0.0 for both groups). There was no statistically significant difference in amount of CMT change between groups (p= 0.470). CSR resolved completely in 81.5% of eyes in the PDT group and 88.9% of eyes in the SML group (p=0.716). During the follow-up period, recurrence of CSR was observed in 3 eyes (11.1%) in the PDT group, and in 3 eyes (7.4%) in the SML group.
Our study results showed similar efficiency of half-fluence PDT and SML treatments in patients with chronic CSR. SML may be an alternative treatment option in chronic CSR, while it has relatively few side effects than PDT, can easily be applied, and does not require additional preventive arrangement after the therapy.